{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"111"}]}],"title":"Improved"},{"categories":[{"measurements":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"144"}]}],"title":"Unchanged"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"39"}]}],"title":"Worsened"}],"denoms":[{"counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"294"}],"units":"Participants"}],"description":"The SF-36 determined participants' overall quality of life by assessing :1) limitations in physical functioning due to health problems; 2) limitations in usual daily activities because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems since last month; 7) limitations in usual work (house hold and outside) due to emotional problems 8) current and 1 year past status of health 9) general mental health. Scores on mental component were summed and averaged (range = 0 \\[worst\\]-100 \\[best\\]); increase from baseline indicated improvement. If participants' had shown change from baseline in mental health score \\>6.33, it was considered as improved; scores between -6.33 to 6.33 was considered unchanged, and score \\<-6.33 was considered as worsened. Change from Baseline = difference between the mental component score at Week 24 and the score at Baseline.","groups":[{"description":"Eligible participants were administered placebo by intravenous infusion on Days 1 and 15 along with MTX 10-25 mg p.o. or parenterally once a week up to 24 weeks and were followed up to Week 104.","id":"OG000","title":"Placebo Plus Methotrexate"},{"description":"Eligible Participants were administered rituximab 1000 mg as intravenous infusion on Days 1 and 15 along with MTX 10-25 mg p.o. or parenterally once a week up to Week 24 and were followed up to Week 104.","id":"OG001","title":"Rituximab Plus Methotrexate"}],"paramType":"NUMBER","populationDescription":"The ITT population included all randomized participants who received any part of an infusion of study drug. Participants with available data at the time of evaluation were analyzed.","reportingStatus":"POSTED","timeFrame":"From Baseline (Day 1) to Week 24","title":"Number of Participants With Change From Baseline in the Mental Component Scores of SF-36","type":"SECONDARY","unitOfMeasure":"participants"}